全志科技(300458.SZ):2019年度計提資產減值準備3193.27萬元
格隆匯4月1日丨全志科技(300458.SZ)公佈,根據《企業會計準則》及公司會計政策、會計估計等相關規定,基於謹慎性原則,公司及下屬子公司對2019年末的各類資產進行了減值測試,並進行分析和評估。經資產減值測試,公司認為部分資產存在一定的減值跡象,公司及下屬子公司對可能發生資產減值的資產進行計提減值準備。
根據測試結果,公司及下屬子公司對2019年度末存在可能發生減值跡象的資產進行全面清查和資產減值測試後,計提2019年度各項資產減值準備3193.27萬元。
公司此次計提資產減值準備金額合計3193.27萬元,使公司2019年度合併報表利潤總額減少3193.27萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.